



Comprehensive COPD care includes screening for alpha-1

AlphaID™ provides fast, easy, and completely free screening for alpha-1, also known as genetic COPD

As a respiratory therapist (RT), you can make a difference in your patients' COPD care by screening for alpha-1 with AlphaID.

GRIFOLS

alpha-1, alpha₁-antitrypsin deficiency; COPD, chronic obstructive pulmonary disease.

Your patients with COPD may have alpha-1 and not know it¹

Patients with an FEV₁/FVC ratio of 0.70 or less should be screened for alpha-1⁶

Alpha-1 is underdiagnosed¹



of patients with alpha-1 remain undiagnosed¹



is the average delay from symptom onset to diagnosis¹

Alpha-1 is the #1 known genetic risk factor for COPD²

- Alpha-1 may be a contributing cause in up to 300,000 cases of COPD in the United States¹
- Alpha-1 affects the body's ability to produce a protein called alpha₁-antitrypsin (AAT), resulting in damage to the lungs³
- Patients with alpha-1 can pass a deficient allele onto their children⁴

Fortunately, there are FDA-approved treatments available for patients with alpha-1⁵

Major respiratory organizations recommend using genetic screening for alpha-1 in all of your patients with COPD^{2,3,7-9}



ATS: American Thoracic Society



CHEST: American College of Chest Physicians



COPD Foundation: Chronic Obstructive Pulmonary Disease

GOLD

GOLD: Global Initiative for Chronic Obstructive Lung Disease

WHO

WHO: World Health Organization

The ATS recommends screening for alpha-1 regardless of age, smoking history, or FEV₁ in⁷:

- All adults with **symptomatic COPD**
- All adults with **uncontrolled asthma**
- All adults with **emphysema**
- People with **alpha-1 in their family**

“ [I screen all my patients with COPD for alpha-1 because I know it's my responsibility to explore all the options so they receive the very best care possible. —Marie, RT] ”



Ruling out alpha-1 is *fast, easy,*
and *completely free* with AlphaID

AlphaID fits easily into your PFT routine



FAST

Gentle cheek swab that only takes seconds

FAMILIAR

Same DNA collection and screening methods as many at-home genetic testing kits

RELIABLE

Delivers accurate and reliable genotyping results¹⁰

SPECIFIC

Screens for the 14 most prevalent mutations associated with alpha-1¹⁰

CONFIDENTIAL

Results are available only to the ordering clinician and designated office staff

COMPLETELY FREE

Provided by Grifols and is not billed to patients or their insurers

If the result is positive, the clinician can use AlphaID™ CONFIRM to determine the AAT level and complete the diagnosis

AlphaID is so fast that you can easily incorporate it either pre- or post-bronchodilation

“ [Why wouldn't you test? I have been screening for many years now. AlphaID is the easiest screening tool we have to help diagnose one of the most prominently missed causes of emphysema. **It is easy, painless, and fast.** We test every nonreversible obstructive flow volume loop in our PFT lab. —Joan, RT] ”

“ [We use AlphaID during PFTs because providing the right kind of care means having all the information. **It's easy and fast and takes very little effort, but can make a big difference in how we treat our patients.** —Tom, RT] ”

“ [My patients' lung health is in my hands so screening for alpha-1 is integral to ensuring that I'm giving them the best care I can. **AlphaID makes this part of my job super easy.** —Brian, Medical Assistant] ”

PFT, pulmonary function test.



You can make a difference by screening for alpha-1, also known as genetic COPD



90% of people with alpha-1 remain **undiagnosed**¹



Major respiratory organizations **recommend genetic screening for alpha-1** in all patients with COPD^{2,3,7-9}



Screening all patients with COPD for alpha-1 will help to ensure that you are providing **comprehensive care**¹



AlphaID is a simple cheek swab test that is **fast, easy, and completely free**, with no insurance required



AlphaID **fits easily into your PFT routine**

Use AlphaID to screen all patients with COPD for alpha-1

To begin screening with AlphaID, contact your Grifols representative or visit requestAlphaID.com

Grifols is committed to supporting patients with alpha-1

Grifols is dedicated to advancing the understanding of alpha-1. Grifols has been the leader in alpha-1 screening for more than 20 years and continues to develop innovative ways to screen patients.

References: 1. Campos MA, Wannner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with α 1-antitrypsin deficiency between 1968 and 2003. *Chest*. 2005;128(3):1179-1186. 2. World Health Organization. α 1-antitrypsin deficiency: memorandum from a WHO meeting. *Bull World Health Organ*. 1997;75(5):397-415. 3. About Alpha-1 Antitrypsin Deficiency. CHEST Foundation website. <https://foundation.chestnet.org/lung-health-a-z/alpha-1-antitrypsin-deficiency>. Accessed January 7, 2021. 4. de Serres FJ, Blanco I, Fernández-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. *Clin Genet*. 2003;64(5):382-397. 5. Current Therapy. Alpha-1 Foundation website. <https://www.alpha1.org/healthcare-providers/testing-and-treatment/current-therapy>. Accessed January 8, 2021. 6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. 7. American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med*. 2003;168(7):818-900. 8. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha1-antitrypsin deficiency in the adult. *J COPD Foundation*. 2016;3(3):668-682. 9. Global Initiative for Chronic Obstructive Lung Disease. Pocket Guide to COPD Diagnosis, Management, and Prevention. 2010:1-28. 10. Data on file, Alpha-1 Genetics Laboratory, Grifols.

GRIFOLS



© 2021 Grifols All rights reserved January 2021 US-PRL-2100027